


Crown Bioscience to provide preclinical and translational services in Japan

12 May 2022 | News

Crown Bioscience and MBL enter joint venture



US-based Crown Bioscience and Medical & Biological Laboratories (MBL), JSR Life Sciences companies, have announced the formation of a joint venture, to further expand the provision of Crown Bioscience's preclinical services to Japanese customers.

The new entity named "Crown Bioscience & MBL", is a long-term strategic partnership that is expected to accelerate growth for both companies. The initial focus is to provide preclinical and translational services to expand Crown Bioscience's offerings in Japan. The agreement will enhance Crown Bioscience's current distributor model and establish a local presence to ensure premium service delivery in Japan.

Based in Tokyo, Crown Bioscience & MBL will establish a local team led by an experienced General Manager, Hiroki Itou, Executive Officer of MBL and General Manager, Diagnostic & Research Reagents Department at JSR.

The new company will leverage each organisations' respective areas of excellence and expertise, combining Crown Bioscience's world-class preclinical and translational service capabilities with MBL's deep knowledge and experience of the Japanese pharmaceutical market. The company, established in April 2022, is expected to initiate services from September 2022.